A Multicenter, Randomized, Double-Blind, Phase 2/3 Study of BCA101 or Placebo in Combination with Pembrolizumab for First Line Treatment of PD-L1-positive, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma